drugset / Trial / NCT00836875

A Study To Evaluate The Safety Of Voriconazole As Treatment Of Invasive Aspergillosis (Fungal Infection) And Other Rare Molds In Children

NCT00836875

Phase 3 Terminated 31 enrolled Pfizer
Non-randomizedOpen-labelTreatment

Summary

The purpose of this study is to evaluate the safety profile of voriconazole (an antifungal drug) when used in children who have invasive aspergillosis (IA) and other rare systemic fungal infections.

Timeline

Start
2009-05
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Voriconazole Small molecule 4 mg/kg Intravenous
Subject Voriconazole Small molecule 8 mg/kg Intravenous
Subject Voriconazole Small molecule 9 mg/kg Intravenous
Subject Voriconazole Small molecule 200 mg Intravenous